CHMP has adopted a negative opinion for the marketing authorization of masitinib in Amyotrophic Lateral Sclerosis
19/04/2018 – AB Science will provide additional data through a reexamination procedure
A Modern View of Liberalism
Praesent nec lectus eu neque fringilla volutpat. Nulla tristique ullamcorper quam, ut dapibus massa hendrerit ac. Etiam a tempus lectus. Proin nibh nisi, vehicula non enim sed, venenatis faucibus orci. Fusce ut elementum nunc, vel eleifend sem.
Career Advancement Launches New Grant Program in Memory of Pat Rosenzweig
Suspendisse ex justo, lacinia nec iverra bel, lacinia id lorem. Sed turpis eget sem accumsan viverra
Defeating the Dakota Access Pipeline at Standing Rock
Nulla dui fusce feugiat malesuada odiorbi nunc odio gravida at cursus nec luctus a lorem aecenas tristique orci acsemuis ultricies pharetra magna.
Corporate Presentation
13/03/2018 – Current status and perspective for 2018.
IDMC recommended the continuation of the masitinib phase 3 study in progressive forms of multiple sclerosis with no requirement to increase the study sample size
04/01/2018 – Additionally, the IDMC did not report any safety concern with masitinib in the study population.
Human Medicine – Inflammatory diseases
European Hematology Association June 2017 22/06/2017 – MASITINIB FOR TREATMENT OF SEVERELY SYMPTOMATIC INDOLENT SYSTEMIC MASTOCYTOSIS: ADDITIONAL EFFICACY ANALYSES FROM THE RANDOMIZED, PLACEBOCONTROLLED, PHASE 3 STUDY
Human Medicine – Oncology
Abstract O. Hermine Industry’s Perspective 2016 01/07/2016 – Development of masitinib, a novel tyrosine kinase inhibitor and immunotherapeutic, for the treatment of peripheral T-cell lymphoma
Mast Cells as a Target
Montagne-Neuron-2015 21/01/2015 – Blood-Brain Barrier Breakdown in the Aging Human Hippocampus Volonte CNSND-DT Author corrected PROOFS 15/12/2014 – New Kid on the Block: Dœs Histamine Get Along with Inflammation in Amyotrophic Lateral Sclerosis? PlosOne – Mast Cells in Gastric Cancer 08/09/2014 – Intratumor IL-17-Positive Mast Cells are the major source of the IL-17 that is…
Basic Research
Comparative analysis of the kinase selectivity profile of masitinib versus other TKIs 25/07/2014 – The knowledge of the selectivity of PKIs is a critical point for the development of optimal safe and well tolerated […] PLoS ONE 2009 Dubreuil – MASITINIB A POTENT c-KIT INHIBITOR 30/09/2009 – Masitinib (AB1010), a Potent and Selective Tyrosine Kinase…